Cargando…

Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function

BACKGROUND: Dose adjustment is often required in patients with normal or enhanced renal function. The aim of this study is to investigate the pharmacokinetic (PK) properties of doripenem and explore optimal dosing regimens in patients with normal or enhanced renal function according to various minim...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, So Won, Choe, Sangmin, Kim, Dong Jin, Zang, Dae Young, Lee, Dong-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075885/
https://www.ncbi.nlm.nih.gov/pubmed/29746394
http://dx.doi.org/10.1097/FTD.0000000000000528
_version_ 1783344623445344256
author Kim, So Won
Choe, Sangmin
Kim, Dong Jin
Zang, Dae Young
Lee, Dong-Hwan
author_facet Kim, So Won
Choe, Sangmin
Kim, Dong Jin
Zang, Dae Young
Lee, Dong-Hwan
author_sort Kim, So Won
collection PubMed
description BACKGROUND: Dose adjustment is often required in patients with normal or enhanced renal function. The aim of this study is to investigate the pharmacokinetic (PK) properties of doripenem and explore optimal dosing regimens in patients with normal or enhanced renal function according to various minimum inhibitory concentrations (MICs). METHODS: The authors conducted a clinical trial and analyzed PK samples in 11 healthy Korean subjects applying noncompartmental analysis and a population approach. The population PK parameter estimates were used in Monte Carlo simulations to explore optimal dosing regimens for a probability of target attainment of 90% at 40% fT(MIC) (free drug concentrations above MIC). RESULTS: The time course of doripenem concentrations was well described by a 2-compartment model. The population typical values of clearance and steady-state volume were 22.9 L/h and 19.1 L, respectively, and were consistent with our noncompartmental analysis results. When the MIC was greater than 1 mcg/mL, at least increasing the dose or prolonging the infusion time was essential in patients with normal or enhanced renal function. CONCLUSIONS: These results suggest that dosage adjustment such as increasing the dose or lengthening the infusion time should be considered in patients with normal or enhanced renal function.
format Online
Article
Text
id pubmed-6075885
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-60758852018-08-17 Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function Kim, So Won Choe, Sangmin Kim, Dong Jin Zang, Dae Young Lee, Dong-Hwan Ther Drug Monit Original Article BACKGROUND: Dose adjustment is often required in patients with normal or enhanced renal function. The aim of this study is to investigate the pharmacokinetic (PK) properties of doripenem and explore optimal dosing regimens in patients with normal or enhanced renal function according to various minimum inhibitory concentrations (MICs). METHODS: The authors conducted a clinical trial and analyzed PK samples in 11 healthy Korean subjects applying noncompartmental analysis and a population approach. The population PK parameter estimates were used in Monte Carlo simulations to explore optimal dosing regimens for a probability of target attainment of 90% at 40% fT(MIC) (free drug concentrations above MIC). RESULTS: The time course of doripenem concentrations was well described by a 2-compartment model. The population typical values of clearance and steady-state volume were 22.9 L/h and 19.1 L, respectively, and were consistent with our noncompartmental analysis results. When the MIC was greater than 1 mcg/mL, at least increasing the dose or prolonging the infusion time was essential in patients with normal or enhanced renal function. CONCLUSIONS: These results suggest that dosage adjustment such as increasing the dose or lengthening the infusion time should be considered in patients with normal or enhanced renal function. Therapeutic Drug Monitoring 2018-08 2018-05-10 /pmc/articles/PMC6075885/ /pubmed/29746394 http://dx.doi.org/10.1097/FTD.0000000000000528 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Kim, So Won
Choe, Sangmin
Kim, Dong Jin
Zang, Dae Young
Lee, Dong-Hwan
Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title_full Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title_fullStr Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title_full_unstemmed Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title_short Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function
title_sort pharmacokinetics of doripenem in healthy koreans and monte carlo simulations to explore optimal dosage regimens in patients with normal and enhanced renal function
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075885/
https://www.ncbi.nlm.nih.gov/pubmed/29746394
http://dx.doi.org/10.1097/FTD.0000000000000528
work_keys_str_mv AT kimsowon pharmacokineticsofdoripeneminhealthykoreansandmontecarlosimulationstoexploreoptimaldosageregimensinpatientswithnormalandenhancedrenalfunction
AT choesangmin pharmacokineticsofdoripeneminhealthykoreansandmontecarlosimulationstoexploreoptimaldosageregimensinpatientswithnormalandenhancedrenalfunction
AT kimdongjin pharmacokineticsofdoripeneminhealthykoreansandmontecarlosimulationstoexploreoptimaldosageregimensinpatientswithnormalandenhancedrenalfunction
AT zangdaeyoung pharmacokineticsofdoripeneminhealthykoreansandmontecarlosimulationstoexploreoptimaldosageregimensinpatientswithnormalandenhancedrenalfunction
AT leedonghwan pharmacokineticsofdoripeneminhealthykoreansandmontecarlosimulationstoexploreoptimaldosageregimensinpatientswithnormalandenhancedrenalfunction